When it comes to scientific discovery, one thing LLMs are really good at is getting hobbyists to delude themselves into believing they've made a huge breakthrough on some longstanding problem or a theory of everything
Science is too slow.
At Edison, we are integrating AI Scientists into the full stack of research, from basic discovery to clinical trials. We want cures for all diseases by mid-century.
We have raised a $70M seed to get started.
Join us.
We need cracked software engineers who want to work on finding cures rather than selling ads and generating slop. If you’re reading this, you’re probably a candidate.
We need brilliant AI researchers who want to figure out how AI will accelerate real-world science.
We need scientists and researchers with deep expertise in biology, biotech, and pharma who want to figure out how to integrate AI deeply into scientific workflows, from ideation to experimentation, and how to measure success or failure.
We need extraordinarily talented generalist operators across BD, sales, product management, and partnerships who can focus on getting our tools into the hands of pharmaceutical companies.
If any of these roles sound like you, get in touch.
We are also expanding access to our platform.
Our goal is to accelerate science writ large. To that end, we will continue to give academics and students 650 credits/mo indefinitely. I can’t promise we’ll keep this up forever, but we will try. Kosmos will still cost 200 credits, and the other agents (Analysis, Literature, etc.) will cost 1 or 2 credits.
All paid users will have access to our regular agents, like our Analysis agent, Literature agent, and so on, for free via the UI. API access will still be paid, and users without a paid subscription will continue to get 10 credits per month for those agents. Our $200/mo subscription for 650 credits/mo is staying in place for now, but might be phased out at our next major product update.
Along the lines of accelerating science, we’re also doing a major release of PaperQA today, our flagship open source literature agent, as part of our commitment to open science.
In the short run, expect major improvements to Kosmos, including the ability to automatically access data, the ability to steer its exploration, and the ability to converse directly with its world model.
In the long run, expect exponentially increasing rates of scientific discoveries, in biology and elsewhere.
Our round is led by Triatomic Capital, Spark Capital, and a major US institutional biotech investor. We are also joined in this round by existing investors Pillar VC and Susa Ventures, two exceptional early-stage funds who backed us at founding, along with Striker Venture Partners, Hawktail VC, Olive VC, and a host of exceptional angels that includes famous AI researchers, the CEOs of multiple frontier AI labs, and leadership of major biotech and pharma companies.
Are you a creative, collaborative scientist looking for your next challenge? We’re seeking awesome colleagues to join us on our quest to design microbial communities for plant-based foods (and other cool projects)! Our beautiful lab space is located in the Brooklyn Navy Yard.🚀
So excited to share that we have not one, two, but SEVEN open positions to join the Kingdom team - we're hiring across RA and Sci levels to help deepen our scientific investment across microbial cultivation, chemistry, imaging, screening and more.
If working with weird microbes and cool toys all day excites you - please get in touch. I feel super lucky to do science with our superstar team every single day, and we're looking for exceptional scientists, engineers and microbe lovers to join us.
The state of software sales in biotech is abysmal. If you’re afraid that I won’t like your product when demoing it, then why should I spend many $100k on it?
Thrilled to share my first, first-author manuscript from my time here in @Doudna_lab with funding from m-CAFEs SFA!
We believe Cas13a will have a bright future across phage biology and engineering. A short 🧵.
TLDR; it works. 1/
https://t.co/eVg8VIWwwV
@srikosuri Brand/connections were obviously pluses but for us at least the office hours were huge. Def depends on partner and nature of business model.
At the time we seeded Illumina, everyone thought it was 1) crazy. 2) using optics to do genotyping-very crazy. 3). How could you compete against dominant players like Affy. Not possible. 4) could never make oligos cheap enough or multiplex them.